Patents by Inventor Raluca Verona

Raluca Verona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating multiple myeloma
    Patent number: 11952426
    Abstract: Methods of treating cancers using a BCMAxCD3 bispecific antibody are described.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: April 9, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Homer Adams, Arnob Banerjee, Suzette Girgis, Jenna Goldberg, Tara Stephenson, Raluca Verona, Shun xin Wang lin
  • METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES
    Publication number: 20230295292
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics. In particular, methods are disclosed of using a GPRC5DxCD3 bispecific antibody, an anti-CD38 antibody and/or pomalidomide to treat cancers.
    Type: Application
    Filed: November 2, 2022
    Publication date: September 21, 2023
    Inventors: Jenna Goldberg, Shun Xin Wang Lin, Thomas J. Prior, Raluca Verona, Brendan Weiss
  • METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF BCMAXCD3 BISPECIFIC ANTIBODIES
    Publication number: 20230272102
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies. In particular, methods are disclosed of using a BCMAxCD3 bispecific antibody, an anti-CD38 antibody and/or pomalidomide to treat cancers, particularly relapsed or refractory multiple myeloma.
    Type: Application
    Filed: November 2, 2022
    Publication date: August 31, 2023
    Inventors: Jenna Goldberg, Jagoda Jasielec, Raluca Verona, Brendan Weiss
  • FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20230030983
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Application
    Filed: March 18, 2022
    Publication date: February 2, 2023
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Jayaprakash KARKERA, Suso Jesus PLATERO, Raluca VERONA, Matthew V. LORENZI
  • BCMA AS A TARGET FOR T CELL REDIRECTING ANTIBODIES IN B CELL LYMPHOMAS
    Publication number: 20220411525
    Abstract: Provided are methods for treating non-Hodgkin lymphoma (NHL) in a human subject comprising administering to the subject a therapeutically effective amount of a BCMA-specific antibody.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 29, 2022
    Inventors: Homer Adams, III, Raluca Verona, Arnon P. Kater, Eric Frederik Eldering
  • USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS
    Publication number: 20220348662
    Abstract: Embodiments of the present invention relate to a method of treating cancer in a patient comprising administering an immune checkpoint inhibitor to the patient, wherein the patient has been diagnosed with an FGFR-genetically altered cancer, and has been pre-treated with an FGFR inhibitor, such as erdafitinib.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 3, 2022
    Inventors: Waleed S. SHALABY, Ademi Elena SANTIAGO-WALKER, Raluca VERONA, Enrique ZUDAIRE
  • METHODS FOR TREATING MULTIPLE MYELOMA
    Publication number: 20220177584
    Abstract: Methods of treating a hematological malignancy using a GPRC5D×CD3 bispecific antibody are described. The hematological malignancy can be a relapsed or refractory multiple myeloma, and the GPRC5D×CD3 bispecific antibody can be talquetamab.
    Type: Application
    Filed: September 16, 2021
    Publication date: June 9, 2022
    Inventors: Suzette Girgis, Jenna Goldberg, Brandi Hilder, Xuewen Ma, Jeffery Russell, Raluca Verona, Shiyi Yang, Kodandaram Pillarisetti
  • Methods for Treating Multiple Myeloma
    Publication number: 20220041742
    Abstract: Methods of treating cancers using a BCMA×CD3 bispecific antibody are described.
    Type: Application
    Filed: May 11, 2021
    Publication date: February 10, 2022
    Inventors: Homer Adams, Arnob Banerjee, Suzette Girgis, Jenna Goldberg, Tara Stephenson, Raluca Verona, Shun xin Wang lin
  • ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
    Publication number: 20210277110
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2020
    Publication date: September 9, 2021
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
    Patent number: 10894830
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A DeAngelis, Sandra Santulli-Marotto, Karla R Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20200108141
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 9, 2020
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Jayaprakash KARKERA, Suso Jesus PLATERO, Raluca VERONA, Matthew V. LORENZI
  • FGFR/PD-1 combination therapy for the treatment of cancer
    Patent number: 10478494
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: November 19, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Jayaprakash Karkera, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
  • ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
    Publication number: 20170121409
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 4, 2017
    Applicant: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen
  • FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20160287699
    Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
    Type: Application
    Filed: March 24, 2016
    Publication date: October 6, 2016
    Inventors: Jayaprakash KARKERA, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi